|
已选(0)清除
条数/页： 排序方式： |
| Characterization of 500 Chinese patients with cervical esophageal cancer by clinicopathological and treatment outcomes 期刊论文
CANCER BIOLOGY & MEDICINE, 2020, 卷号: 17
-
  收藏 | 浏览/下载：37/0 | 提交时间：2020/10/26
GENOME-WIDE ASSOCIATION SQUAMOUS-CELL CARCINOMA Cervical esophageal cancer survival esophagectomy radiochemotherapy |
| The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression 期刊论文
CELL RESEARCH, 2020, 卷号: 30
-
收藏 | 浏览/下载：56/0 | 提交时间：2020/10/26
OXIDATIVE STRESS CANCER SULFASALAZINE RADIOTHERAPY PEROXIDATION TRANSPORTER HOMEOSTASIS INHIBITION CHECKPOINT ANTIPORTER |
| 阿帕替尼联合放化疗治疗非小细胞肺癌脑转移患者的近期疗效与安全性 期刊论文
中国肿瘤生物治疗杂志, 2020, 卷号: 27
作者: 尹雪; 胡宗涛; 徐秀理; 张文康; 崔相利 ; 高世乐
收藏 | 浏览/下载：35/0 | 提交时间：2020/10/26
non-small cell lung cancer (NSCLC) brain metastasis apatinib concurrent radiochemotherapy short-term efficacy safety 非小细胞肺癌 脑转移 阿帕替尼 同步放化疗 近期疗效 安全性 |
| Coagulation factors VII, IX and X are effective antibacterial proteins against drug-resistant Gram-negative bacteria 期刊论文
CELL RESEARCH, 2019, 卷号: 29
-
收藏 | 浏览/下载：40/0 | 提交时间：2020/10/26
PSEUDOMONAS-AERUGINOSA ANTIMICROBIAL PEPTIDES ESCHERICHIA-COLI POLYMYXIN-B RECOGNITION BINDING LIPOPOLYSACCHARIDE ANTIBIOTICS HEMOPHILIA DEFICIENCY |
| Targeting slug-mediated non-canonical activation of c-Met to overcome chemo-resistance in metastatic ovarian cancer cells 期刊论文
ACTA PHARMACEUTICA SINICA B, 2019, 卷号: 9
-
收藏 | 浏览/下载：31/0 | 提交时间：2020/10/26
EPITHELIAL-MESENCHYMAL TRANSITION TUMOR-GROWTH HETEROGENEITY AMPLIFICATION CONTRIBUTES PROGRESSION CARCINOMA REVEALS PATHWAY SNAIL Slug c-Met Drug resistance Ovarian cancer XL184 |
| Association between Chinese Medicine Therapy and Survival Outcomes in Postoperative Patients with NSCLC: A Multicenter, Prospective, Cohort Study 期刊论文
CHINESE JOURNAL OF INTEGRATIVE MEDICINE, 2019, 卷号: 25
作者: Wang Xueqian; Zhang Ying; Hou Wei; Wang Yingtian; Zheng Jiabin; Li Jie; Lin Lizhu; Jiang Yilan; Wang Shenyu; Xie Ying; Zhang Hongliang; Shu Qijin; Li Ping; Wang Wei; You Jianliang; Li Ge; Liu Jie; Fan Huiting; Zhang Meiying; Lin Hongsheng
收藏 | 浏览/下载：25/0 | 提交时间：2020/10/26
CELL LUNG-CANCER ADJUVANT CHEMOTHERAPY Chinese medicine non-small cell lung cancer postoperative care cohort study disease-free survival |
| Prevalence and clinical significance of pathogenic germline BRCA1 2 mutations in Chinese non-small cell lung cancer patients 期刊论文
Cancer Biology & Medicine, 2019, 卷号: 16
作者: Hu Xingsheng; Yang Dongyong; Li Yalun; Li Li; Wang Yan; Chen Peng; Xu Song; Pu Xingxiang; Zhu Wei; Deng Pengbo; Yen Junyi; Zhang Hanhan; Lizaso Analyn; Liu Hao; Mao Xinru; Huang Hai; Chu Qian; Hu Chengping
收藏 | 浏览/下载：61/0 | 提交时间：2020/12/28
SUSCEPTIBILITY LOCUS PROSTATE-CANCER OVARIAN-CANCER BREAST RISK MULTICENTER EXPRESSION INHIBITORS VARIANTS CARRIERS Germline BRCA mutations non-small cell lung cancer prevalence BRCA1 BRCA2 |
| Tumor suppressor miR-128-3p inhibits metastasis and epithelial-mesenchymal transition by targeting ZEB1 in esophageal squamous-cell cancer 期刊论文
ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2018, 卷号: 50
-
收藏 | 浏览/下载：32/0 | 提交时间：2020/10/26
ACUTE LYMPHOBLASTIC-LEUKEMIA GENOME-WIDE ASSOCIATION EMT-ACTIVATOR ZEB1 CIRCULATING MICRORNAS TRANSCRIPTION FACTORS PROMOTES INVASION MIRNA EXPRESSION FEEDBACK LOOP CARCINOMA SURVIVAL miR-128-3p esophageal squamous-cell carcinoma ZEB1 epithelial-mesenchymal transition invasion and metastasis |
| Clinicopathological features and surgical outcomes of four rare subtypes of primary liver carcinoma 期刊论文
CHINESE JOURNAL OF CANCER RESEARCH, 2018, 卷号: 30
-
收藏 | 浏览/下载：29/0 | 提交时间：2020/10/26
SARCOMATOID HEPATOCELLULAR-CARCINOMA CLEAR-CELL CARCINOMA OF-THE-LITERATURE CHOLANGIOCELLULAR CARCINOMA GIANT-CELLS CHOLANGIOCARCINOMA DIAGNOSIS SURGERY Clear cell carcinoma combined hepatocellular-cholangiocarcinoma giant cell carcinoma sarcomatoid carcinoma hepatocellular carcinoma |
| The prognostic value of programmed cell death ligand 1 expression in non-Hodgkin lymphoma: a meta-analysis 期刊论文
CANCER BIOLOGY & MEDICINE, 2018, 卷号: 15
-
收藏 | 浏览/下载：27/0 | 提交时间：2020/10/26
PD-L1 EXPRESSION POOR CANCER Meta-analysis non-Hodgkin lymphoma (NHL) programmed cell death ligand 1 (PD-L1) prognosis |
